natgillin/translations-raw huggingface dataset:
Because Darunavir Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Ker je zdravilo Darunavir Mylan generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Darunavir Mylan has been shown to have comparable quality and to be bioequivalent to Prezista.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Darunavir Mylan primerljivo raven kakovosti kot zdravilo Prezista ter da mu je biološko enakovredno.
As for every medicine, the company provided studies on the quality of Darunavir Mylan.
Kot to velja za vsako zdravilo, je družba zagotovila študije o kakovosti zdravila Darunavir Mylan.
The Committee recommended that Darunavir Mylan be approved for use in the EU.
Priporočil je, da se zdravilo Darunavir Mylan odobri za uporabo v EU.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Darunavir Mylan have been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo zdravstveni delavci in bolniki upoštevati za varno in učinkovito uporabo zdravila Darunavir Mylan, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
Studies on the benefits and risks of the active substance in the approved use have already been carried out with the reference medicine, Prezista, and do not need to be repeated for Darunavir Mylan.
Študije o koristih in tveganjih zdravilne učinkovine pri dovoljenih uporabah so že bile izvedene z referenčnim zdravilom Prezista, zato jih ni treba ponoviti za zdravilo Darunavir Mylan.
What measures are being taken to ensure the safe and effective use of Darunavir Mylan?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Darunavir Mylan?
This means that Darunavir Mylan contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the European Union (EU) called Prezista.
To pomeni, da vsebuje enako zdravilno učinkovino in ima enak način delovanja kot referenčno zdravilo Prezista, ki je že odobreno v Evropski uniji (EU).
Darunavir Mylan, taken in combination with other HIV medicines, reduces the amount of HIV in the blood and keeps it at a low level.
Zdravilo Darunavir Mylan v kombinaciji z drugimi protivirusnimi zdravili zniža količino virusa HIV v krvi in jo vzdržuje na nizki ravni.
Darunavir Mylan is an antiviral medicine used with other HIV medicines to treat patients with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Darunavir Mylan je protivirusno zdravilo, ki se uporablja v kombinaciji z drugimi zdravili za zdravljenje okužbe z virusom HIV pri bolnikih, okuženih z virusom človeške imunske pomanjkljivosti tipa 1 (HIV1), tj. virusom, ki povzroča sindrom pridobljene imunske pomanjkljivosti (aids).
What are the benefits and risks of Darunavir Mylan?
Kakšne so koristi in tveganja, povezani z zdravilom Darunavir Mylan?
The medicine is always taken either with cobicistat (in adults) or with low-dose ritonavir (in adults and children) and with other HIV medicines, and should be taken with food.
Zdravilo Darunavir Mylan se vedno jemlje bodisi v kombinaciji s kobicistatom (pri odraslih) bodisi v kombinaciji z nizkimi odmerki ritonavirja (pri odraslih in otrocih) in z drugimi zdravili za zdravljenje okužbe s HIV, pri čemer ga je treba jemati sočasno s hrano.
For more information about treatment with Darunavir Mylan, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Darunavir Mylan preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
For children aged 3 to 17 years and weighing at least 15 kg who have not be treated before, the recommended dose varies between 600 and 800 mg once daily depending on their weight.
Pri otrocih, starih od tri do 17 let, ki tehtajo vsaj 15 kg in niso bili predhodno zdravljeni, je priporočeni odmerek med 600 in 800 mg enkrat na dan, odvisno od njihove telesne mase.
Darunavir Mylan does not cure HIV infection or AIDS, but HIV treatment may hold off the damage to the immune system and the development of infections and diseases associated with AIDS.
Zdravilo Darunavir Mylan ne zdravi okužbe z virusom HIV ali aidsa, lahko pa upočasni slabšanje imunskega sistema ter razvoj okužb in bolezni, povezanih z aidsom.
Therefore, the CHMP's view was that, as for Prezista, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi enako kot pri zdravilu Prezista odtehtajo znana tveganja.
It is not intended to provide practical advice on how to use Darunavir Mylan.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
For previously treated children the usually recommended dose varies between 375 and 600 mg twice a day depending on their weight.
Pri predhodno zdravljenih otrocih znaša običajni priporočeni odmerek med 375 in 600 mg dvakrat na dan, odvisno od njihove telesne mase.
Ritonavir and cobicistat reduce the breakdown of darunavir, increasing the levels of darunavir in the blood.
Ritonavir in kobicistat upočasnjujeta hitrost razgradnje darunavirja in s tem povečujeta njegove ravni v krvi.
Other information about Darunavir Mylan
Druge informacije o zdravilu Darunavir Mylan
What is Darunavir Mylan and what is it used for?
Kaj je zdravilo Darunavir Mylan in za kaj se uporablja?
For practical information about using Darunavir Mylan, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Darunavir Mylan naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Darunavir Mylan is a ‘generic medicine'.
Zdravilo Darunavir Mylan je „generično zdravilo“.
Darunavir Mylan can only be obtained with a prescription and treatment should be started by a healthcare professional who has experience in the management of HIV infection.
Predpisovanje in izdaja zdravila Darunavir Mylan je le na recept, zdravljenje z njim pa mora uvesti zdravnik specialist, ki ima izkušnje z zdravljenjem okužbe z virusom HIV.
The active substance in Darunavir Mylan, darunavir, is a protease inhibitor.
Zdravilna učinkovina zdravila Darunavir Mylan, darunavir, je zaviralec proteaze.
Darunavir Mylan is always given with ritonavir or cobicistat.
Zdravilo Darunavir Mylan se vedno daje v kombinaciji z ritonavirjem ali kobicistatom.
The company also carried out studies that showed that it is ‘bioequivalent' to the reference medicine.
Opravila je tudi študije, ki so pokazale, da je zdravilo Darunavir Mylan biološko enakovredno referenčnemu zdravilu.
Why is Darunavir Mylan approved?
Zakaj je bilo zdravilo Darunavir Mylan odobreno?
For adults who have not been treated before, the recommended dose is 800 mg once a day.
Priporočeni odmerek zdravila za odrasle, ki predhodno še niso bili zdravljeni, je 800 mg enkrat na dan. Priporočeni odmerek zdravila za odrasle, ki so že bili predhodno zdravljeni, je 600 mg dvakrat na dan.
Darunavir Mylan contains the active substance darunavir.
Zdravilo Darunavir Mylan vsebuje zdravilno učinkovino darunavir.
How is Darunavir Mylan used?
Kako se zdravilo Darunavir Mylan uporablja?
How has Darunavir Mylan been studied?
Kako je bilo zdravilo Darunavir Mylan raziskano?
How does Darunavir Mylan work?
Kako zdravilo Darunavir Mylan deluje?
Adopted at the 10-13 May 2016 PRAC
Sprejeto na seji odbora PRAC med 10. in 13. majem 2016
• Severe diarrhoea
• hudo drisko
Tell your doctor straight away if you have any of the following side effects…:
Nemudoma obvestite svojega zdravnika, če opazite katerega od naslednjih neželenih učinkov:
Warfarin - Calciphylaxis (EPITT no 18545)
Varfarin - kalcifilaksija (EPITT št. 18545)
Serious cases of ARN, either affecting one or both eyes, led to blindness in some patients.
Resni primeri ARN, ki so prizadeli eno ali obe očesi, so pri nekaterih bolnikih povzročili slepoto.
Infections, including PML and opportunistic infections […] The duration of treatment with TYSABRI prior to onset ranged from a few months to several years (see section 4.4).
Okužbe, vključno s PML in drugimi oportunističnimi okužbami […] Zdravljenje z zdravilom TYSABRI pred pojavom simptomov je trajalo od nekaj mesecev do več let (glej poglavje 4.4).
• An unexplained fever
• nepojasnjeno povišano telesno temperaturo
Natalizumab - Necrotising retinitis (EPITT no 18605)
Natalizumab - nekrotizirajoči retinitis (EPITT št. 18605)
This adverse reaction occurs more frequently in patients with chronic kidney disease.
Ta neželeni učinek se pogosteje pojavi pri bolnikih s kronično ledvično boleznijo.
Section 4.8 - Undesirable effects Skin and subcutaneous tissue disorders Frequency ‘not known': Calciphylaxis
Poglavje 4.8 - Neželeni učinki Bolezni kože in podkožja Pogostnost „neznana“: kalcifilaksija
The treatment reported in these cases included antiviral therapy and in some cases, surgery (see section 4.4).
Zdravljenje teh bolnikov je bilo protivirusno in, v nekaterih primerih, kirurško (glejte poglavje 4.4).
Section 4.4 - Special warnings and precautions for use Infections including other opportunistic infections
Poglavje 4.4 - Posebna opozorila in previdnostni ukrepi Okužbe, vključno z drugimi oportunističnimi okužbami
The condition is mainly observed in patients with end-stage renal disease on dialysis or in patients with known risk factors such as protein C or S deficiency, hyperphosphataemia, hypercalcaemia or hypoalbuminaemia.
Največkrat se pojavi pri bolnikih z zadnjim stadijem bolezni ledvic na dializi ali pri bolnikih z znanimi dejavniki tveganja, kot so pomanjkanje proteinov C ali S, hiperfosfatemija, hiperkalciemija ali hipoalbuminemija.
Patients presenting with eye symptoms such as decreased visual acuity, redness and painful eye should be referred for retinal screening for ARN.
Bolnike s simptomi, kot so zmanjšana ostrina vida, pordelost in bolečine v očesu je treba napotiti na pregled mrežnice za diagnozo ARN.
Acute retinal necrosis (ARN) is a rare fulminant viral infection of the retina caused by the family of herpes viruses (e.g. varicella zoster).
Akutna retinalna nekroza (ARN) je redka fulminantna virusna okužba mrežnice, ki jo povzroči družina herpes virusov (npr. varicella zoster).
On rare occasions warfarin can cause serious skin conditions, including one called calciphylaxis that can start with a painful skin rash but can lead to other serious complications.
V redkih primerih lahko varfarin povzroči resna kožna obolenja, vključno s t.i. kalcifilaksijo, ki se lahko začne z bolečim kožnim izpuščajem, a lahko vodi do pojava drugih resnih zapletov.
[…] If herpes encephalitis or meningitis occurs, TYSABRI should be discontinued and appropriate treatment for herpes encephalitis or meningitis should be administered.
[…]Če pride do herpesnega encefalitisa ali meningitisa, je treba zdravljenje z zdravilom TYSABRI prekiniti in začeti ustrezno zdravljenje herpesnega encefalitisa ali meningitisa.
Some cases have occurred in patients with central nervous system (CNS) herpes infections (e.g. herpes meningitis and encephalitis).
Nekateri primeri so se pojavili pri bolnikih z okužbami osrednjega živčnega sistema s herpesom (npr. herpesnim meningitisom in encefalitisom).
Calciphylaxis is a rare syndrome of vascular calcification with cutaneous necrosis, associated with high mortality.
Kalcifilaksija je redek sindrom vaskularne kalcifikacije s kožno nekrozo, povezana z visoko smrtnostjo.
In case calciphylaxis is diagnosed, appropriate treatment should be started and consideration should be given to stopping treatment with warfarin.
Če se ugotovi kalcifilaksija, je treba začeti s primernim zdravljenjem in razmisliti o prekinitvi zdravljenja z varfarinom.
A painful skin rash.
boleč izpuščaj na koži.
In post-marketing experience, rare cases of acute retinal necrosis (ARN) have been observed in patients receiving TYSABRI.
V obdobju po prihodu zdravila na trg so bili pri bolnikih, ki so prejemali zdravilo TYSABRI, opaženi redki primeri akutne retinalne nekroze (ARN).
Rare cases of calciphylaxis have been reported in patients taking warfarin, also in the absence of renal disease.
Redki primeri pojava kalcifilaksije so bili opaženi pri bolnikih, ki so jemali varfarin, tudi če niso imeli ledvične bolezni.
Following clinical diagnosis of ARN, discontinuation of TYSABRI should be considered in these patients.
Če je ARN klinično potrjena, je treba pri teh bolnikih razmisliti o prekinitvi zdravljenja z zdravilom TYSABRI.
ARN has been observed in patients being administered TYSABRI and can be potentially blinding.
Opazili so jo pri bolnikih, ki so prejemali zdravilo TYSABRI, in lahko povzroči slepoto.
• Impaired vision • Pain or redness of the eye(s)
• okvaro vida • bolečino ali pordelostjo enega ali obeh očes
5 ml (50 mg/ml) 2 pre-filled syringes + 2 safety needles
5 ml (50 mg/ml) 2 napolnjena injekcijska brizga + 2 varnostni igli
5 ml (50 mg/ml) 1 pre-filled syringe + 1 safety needle
5 ml (50 mg/ml) 1 napolnjena injekcijska brizga + 1 varnostna igla
*Relative Potency by a mice potency test compared to a reference vaccine that was shown efficacious in calves.
* Relativna potenca pri testu potence pri miših v primerjavi z referenčnim cepivom, ki je bilo učinkovito pri teletih.
Withdrawal period hydrolytic glass vials type I (EP) with butyl stopper (EP) and aluminium seal
Karenca viale iz hidrolitičnega stekla tipa I (EP) z butilnim zamaškom (EP) in alumijsko zaporko
20ml (10 doses)
240 ml odmerkov)
Approximately 75% of the administered [
Približno 75 % danega [
Date of first authorisation: 03 April 2001 Date of latest renewal: 24 April 2006
Datum prve odobritve: 3.april.2001 Datum zadnjega podaljšanja: 24. april 2006
Elderly The clinical experience in patients over 75 years of age is limited.
Starejši bolniki Klinične izkušnje pri bolnikih, starejših od 75 let, so omejene.
Approximately 6-16% of the administered dose was excreted in the urine as unchanged drug.
Približno 6-16 % danega odmerka se je izločilo v urinu v obliki nespremenjenega zdravila.
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.
Zahteve glede predložitve rednega posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/EC, in vseh kasnejših posodobitvah, objavljenih na evropskem spletnem portalu o zdravilih.
Bear this in mind if you drive a car or operate machines as you might put yourself or others at risk.
Ne pozabite na to, kadar vozite ali upravljate s stroji, saj bi lahko ogrožali sebe in druge.
Even though you are taking medicines for your diabetes, it is important to keep following the diet and/or exercise programme your doctor has recommended for you.
Čeprav jemljete zdravila za sladkorno bolezen, je pomembno, da se še naprej držite diete in/ali programa telesne vadbe, ki vam ju je priporočil vaš zdravnik.
Not all pack sizes or tablet strengths may be available in your country.
Morda vse velikosti pakiranj ali vse jakosti tablet niso na voljo v vaši državi.
Frequencies are defined as: very common (1/10); common (1/100 to <1/10); uncommon (1/1,000 to <1/100); rare (1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).
Pogostnost je definirana takole: zelo pogosti (1/10); pogosti (1/100 do <1/10); občasni (1/1.000 do <1/100); redki (1/10.000 do <1/1.000); zelo redki (<1/10.000); pogostnost neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Adults Nateglinide should be taken within 1 to 30 minutes before meals (usually breakfast, lunch and dinner).
Odrasli Nateglinid je treba jemati 1 do 30 minut pred obroki (navadno pred zajtrkom, kosilom in večerjo).
Both treatments were well tolerated.
Obe kombinaciji zdravil so bolniki dobro prenašali.
• Pregnancy and breast-feeding (see section 4.6)
• med nosečnostjo in dojenjem (glejte poglavje 4.6);
If you forget to take a tablet, simply take the next one before your next meal.
Če pozabite vzeti tableto, preprosto vzemite naslednjo tableto pred naslednjim obrokom.
Starlix can be used by people over 65 years of age.
Zdravilo Starlix lahko uporabljajo tudi ljudje, starejši od 65 let.
Rare: Elevations in liver enzymes.
Redko: zvišanje jetrnih encimov.
These symptoms can also be caused by lack of food or too high a dose of any anti-diabetic medicine you are taking.
Navedene simptome lahko povzroči tudi pomanjkanje hrane ali prevelik odmerek kakega zdravila za sladkorno bolezen, ki ga jemljete.
As nateglinide is highly protein-bound, dialysis is not an efficient means of removing it from the blood.
Ker je nateglinid v veliki meri vezan na beljakovine, dializa ni učinkovito sredstvo za odstranjevanje tega zdravila iz krvi.
• Type 1 diabetes (C-peptide negative)
• s sladkorno boleznijo tipa 1 (na C-peptid negativna sladkorna bolezen);
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
• s preobčutljivostjo na učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1;
If this happens to you, eat or drink something containing sugar, and talk to your doctor.
Če pride od tega, pojejte ali popijte nekaj kar vsebuje sladkor in obvestite svojega zdravnika.
Follow all instructions given to you by your doctor, pharmacist or nurse carefully, even if they are different from what is in this leaflet.
Skrbno se ravnajte po vseh navodilih, ki vam jih dajo vaš zdravnik, farmacevt ali medicinska sestra, tudi če se razlikujejo od informacij v tem navodilu za uporabo.
Such patients should take special care to avoid low blood sugar.
Ti bolniki morajo še posebno paziti, da ne pride do znižanja vrednosti krvnega sladkorja.
Starlix is not recommended for children and adolescents (under 18 years of age) because its effects in this age group have not been studied.
Uporaba zdravila Starlix ni priporočena za otroke in mladostnike (stare manj kot 18 let), ker delovanja zdravila v tej starostni skupini niso proučevali.
Insulin is a substance produced in the body by the pancreas.
Insulin je snov, ki ga v telesu izdeluje trebušna slinavka.
The dosage of nateglinide should be determined by the physician according to the patient's requirements.
Odmerjanje nateglinida mora določiti zdravnik v skladu z bolnikovimi potrebami.
There is no experience in pregnant women, therefore the safety of Starlix in pregnant women cannot be assessed.
Ni izkušenj o uporabi pri nosečnicah, zato varnost uporabe zdravila Starlix pri nosečnicah ne more biti ocenjena.
Take Starlix before the three main meals, usually: - 1 dose before breakfast - 1 dose before lunch - 1 dose before dinner
Zdravilo Starlix zaužijte pred tremi glavnimi obroki, navadno: - 1 odmerek pred zajtrkom, - 1 odmerek pred kosilom, - 1 odmerek pred večerjo.
These are symptoms of low blood sugar (hypoglycaemia), which are usually mild.
Gre za simptome nizkega krvnega sladkorja (hipoglikemije), ki so običajno blagi.
Alcohol may disturb the control of your blood sugar so you are advised to talk to your doctor about drinking alcohol while taking Starlix.
Alkohol lahko poruši uravnavanje vašega krvnega sladkorja, zato je priporočljivo, da se glede uživanja alkohola v času jemanja zdravila Starlix posvetujete z zdravnikom.
Although it is not known whether nateglinide is excreted in human milk, the potential for hypoglycaemia in breast-fed infants may exist and therefore nateglinide should not be used in lactating women.
Čeprav ni znano, ali se nateglinid izloča v materino mleko pri človeku, lahko pri dojenih dojenčkih obstaja potencial za hipoglikemijo, zato se nateglinid pri doječih materah ne sme uporabljati.
The effect of Starlix on the ability to drive or operate machinery has not been studied.
Vpliva zdravila Starlix na sposobnost vožnje in upravljanja s stroji niso proučevali.
Pharmacotherapeutic group: D-phenylalanine derivative, ATC code: A10 BX 03
Farmakoterapevtska skupina: derivati D-fenilalanina, oznaka ATC: A10 BX 03
Electrophysiological studies demonstrate that nateglinide has 45-300-fold selectivity for pancreatic beta cell versus cardiovascular K
Elektrofiziološke študije kažejo, da ima nateglinid 45-300-kratno selektivnost za pankreatično celico beta v primerjavi s kardiovaskularnimi kanalčki K
In a clinical study in patients, Starlix was administered in increasing doses up to 720 mg a day for 7 days and was well tolerated.
V klinični študiji so bolniki prejeli zdravilo Starlix v naraščajočih odmerkih do 720 mg na dan 7 dni dolgo in so ga bolniki dobro prenašali.
Post-marketing data revealed very rare cases of erythema multiforme.
Izkušnje po prihodu zdravila na trg Postmarketinški podatki so razkrili zelo redke primere multiformnega eritema.
If any of these apply to you, do not take Starlix and talk to your doctor.
Če karkoli od navedenega velja za vas, ne jemljite zdravila Starlix, ampak se posvetujte s svojim zdravnikom.
Watch carefully for signs of low blood sugar, especially: - if you have exercised more strenuously than usual.
Bodite pozorni na znake nizkega krvnega sladkorja, zlasti še: - če ste se pri telesni aktivnosti bolj naprezali kot navadno, - če ste pili alkohol.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor, pharmacist or nurse for advice before taking this medicine.
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro, preden vzamete to zdravilo.
Nateglinide is an amino acid (phenylalanine) derivative, which is chemically and pharmacologically distinct from other antidiabetic agents.
Nateglinid je derivat aminokisline (fenilalanina), ki se kemijsko in farmakološko razlikuje od drugih antidiabetikov.
If you have type 2 diabetes, your body may not start producing insulin quickly enough after meals.
Če imate sladkorno bolezen tipa 2, vaše telo po zaužitju hrane ne začne izdelovati insulina dovolj hitro.
Insulin levels return to baseline within 3 to 4 hours, reducing post-meal hyperinsulinaemia.
Koncentracija insulina se vrne na izhodiščno vrednost v 3 do 4 urah, kar zmanjša postprandialno hiperinsulinemijo.
If you have low blood sugar you may experience sweating, tremors (feeling shaky), anxiety, difficulty concentrating, confusion, weakness or fainting or have other signs listed in section 4, “Possible side effects”.
Če imate nizek krvni sladkor, lahko pride do znojenja, tremorja (občutka tresenja), tesnobe, težav z zbranostjo, zmedenosti, šibkosti ali izgube zavesti ali do drugih znakov, ki so navedeni v poglavju 4, “Možni neželeni učinki”.
If you have to go to a doctor or hospital, take the pack and this leaflet with you.
Če morate k zdravniku ali v bolnišnico, vzemite škatlo z zdravilom in to navodilo za uporabo seboj.
Starlix tablets start to act within a very short time after they are swallowed and are eliminated from the body rapidly.
Tablete zdravila Starlix začnejo delovati kmalu po zaužitju in se hitro izločijo iz telesa.
It helps to control the level of sugar in the blood.
Zdravilo pomaga uravnavati vrednost sladkorja v krvi.
CYP2C9 and CYP3A4 substrates
Substrati CYP2C9 in CYP3A4
Starlix is contraindicated in patients with:
Zdravilo Starlix je kontraindicirano pri bolnikih:
A number of medicinal products influence glucose metabolism and possible interactions should therefore be taken into account by the physician.
Več zdravil vpliva na presnovo glukoze, zato mora zdravnik upoštevati možne interakcije.
Starlix is used to treat adult patients with type 2 diabetes.
Zdravilo Starlix uporabljamo pri zdravljenju odraslih bolnikov s sladkorno boleznijo tipa 2.